Sanjiv.Parant.

- There is no explicit mention of any current or planned fundraising through debt or equity in the call transcript. - The company reported existing debt of INR 5 crores and cash equivalents of INR 5.2 crores as of September 2024. - They have indicated expected capex of around INR 3.5 crores for the base business in FY25 and INR 35-40 crores for the HAL venture in FY25. - The company seems focused on internal capital allocation and managing working capital efficiently to support growth. - No direct commentary on raising additional funds through debt or equity was made during the call.

- Capex for the base business was INR 1.46 crores in H1 FY25; expected to be around INR 3.5 crores for FY25 and INR 5.5 crores for FY26. - HAL venture (IV business) capex expected to be around INR 35-40 crores for FY25. - New facility in Pune for infusion project is in pipeline and undergoing various approvals; requiring additional capital and technical hires. - Plant upgrades nearly completed at the Bombay facility; Dehradun facility upgrades to begin soon. - Potential future expansions in Prague facility targeting EUR 8-10 million revenue with possibility of adding a bigger facility. - Discussions ongoing for new projects similar to HAL, but details are not disclosed yet due to competitive reasons.

- Nutraceutical market is constantly growing globally, presenting strong demand growth potential. - Prague JV business expected to stabilize by Q1 FY26, with annual topline of approx. EUR3.5-4 million initially. - Medium to long-term potential for Prague facility estimated at EUR8-10 million annually by FY27, with scope for expansion. - HAL facility peak revenue potential around INR 105-110 crores with 19% EBITDA margin; capacity utilization expected to reach 95-100% within a few months of operation. - Base business sees growth driven by geographic expansion, new product launches (targeting 15-20 launches annually), and increased penetration in existing markets. - Export-driven growth with current export to domestic sales mix approximately 72:28. - Industry challenges like supply chain disruptions and freight costs may impact short-term, but overall outlook remains optimistic.

- Nutraceutical market is expected to grow constantly worldwide, supporting uplift in related revenues. - Prague facility (JV) projected to stabilize by Q1 FY26 with an annual revenue estimate of EUR3.5-4 million and EBITDA margins of 25%-30%. - Medium to long term potential from Prague entity estimated at EUR8-10 million annually post-expansion by FY27. - HAL facility expected to reach peak revenue of INR105-110 crores with EBITDA margins around 19%, achieving near full capacity utilization within a few months. - The company targets launching 15-20 new products annually to expand product portfolio and improve margins over time. - Employee costs to increase due to hiring technical expertise for new facilities and projects, linked with growth. - Overall growth driven by product launches, market penetration, and expansion into new geographies. - Management expects to deliver on commitments and grow the company phenomenally over next couple of years if current demand trends and stability continue.

- Sanjivani Paranteral Limited is currently executing a few small orders for its Prague facility and is in discussions with several big players to move their products into the facility. - For the Prague nutraceutical business, big orders are under discussion but not yet confirmed; conversion to confirmed orders is expected within a quarter or two. - The company has pending approvals for certain products affecting order execution and revenue recognition timing. - Discussions for additional projects similar to the HAL venture are ongoing, but details cannot be disclosed currently due to competitive reasons. - The company expects stabilization of the Prague facility by Q1 next year, with revenue estimated at EUR3.5 to 4 million annually initially, potentially scaling up to EUR8 to 10 million with expansion by FY27. - HAL joint venture projects are on track, with expectations for full production capacity and peak revenues of INR105-110 crores.